Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up.

Jensen KC, Turbin DA, Leung S, Miller MA, Johnson K, Norris B, Hastie T, McKinney S, Nielsen TO, Huntsman DG, Gilks CB, West RB.

Breast Cancer Res Treat. 2008 Dec;112(3):453-9. doi: 10.1007/s10549-007-9887-y. Epub 2008 Jan 9.

PMID:
18193353
2.

Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.

Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.

Oncol Rep. 2008 Mar;19(3):651-6.

PMID:
18288397
3.

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.

Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM.

J Clin Oncol. 2006 Jul 1;24(19):3019-25. Epub 2006 Jun 5.

PMID:
16754938
4.

Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.

Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF.

J Clin Oncol. 2005 Jul 1;23(19):4287-97.

PMID:
15994142
5.
6.

Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.

Shah SS, Wang Y, Tull J, Zhang S.

Diagn Mol Pathol. 2009 Mar;18(1):30-3. doi: 10.1097/PDM.0b013e31817c1af8.

PMID:
19214111
7.

Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations.

Chibon F, de Mascarel I, Sierankowski G, Brouste V, Bonnefoi H, Debled M, Mauriac L, MacGrogan G.

Mod Pathol. 2009 Mar;22(3):403-9. doi: 10.1038/modpathol.2008.195. Epub 2008 Dec 5.

8.

HER2 status in breast cancer determined by IHC and FISH: comparison of the results.

Mrozkowiak A, Olszewski WP, Piaścik A, Olszewski WT.

Pol J Pathol. 2004;55(4):165-71.

PMID:
15757204
9.

Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma.

Krishnamurti U, Hammers JL, Atem FD, Storto PD, Silverman JF.

Mod Pathol. 2009 Aug;22(8):1044-8. doi: 10.1038/modpathol.2009.61. Epub 2009 Apr 24.

10.

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Rüschoff J.

Breast Cancer Res. 2007;9(5):R68.

11.

Absence of HER2 overexpression in metastatic malignant melanoma.

Inman JL, Kute T, White W, Pettenati M, Levine EA.

J Surg Oncol. 2003 Oct;84(2):82-8.

PMID:
14502781
12.

Prognostic significance of HER2 gene amplification according to stage of breast cancer.

Kim YS, Won YS, Park KS, Song BJ, Kim JS, Oh SJ, Jeon HM, Jung SS, Park WC.

J Korean Med Sci. 2008 Jun;23(3):414-20. doi: 10.3346/jkms.2008.23.3.414.

13.

Current issues in ER and HER2 testing by IHC in breast cancer.

Gown AM.

Mod Pathol. 2008 May;21 Suppl 2:S8-S15. doi: 10.1038/modpathol.2008.34. Review.

14.

Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.

Peiró G, Aranda FI, Adrover E, Niveiro M, Alenda C, Payá A, Seguí J.

Hum Pathol. 2007 Jan;38(1):26-34. Epub 2006 Oct 23.

PMID:
17056098
15.

Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.

Kounelis S, Kapranos N, Malamos N, Kouri-Bairaktari E.

Anticancer Res. 2005 Mar-Apr;25(2A):939-46.

16.

The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer.

Steffensen KD, Waldstrøm M, Jeppesen U, Jakobsen E, Brandslund I, Jakobsen A.

Int J Gynecol Cancer. 2007 Jul-Aug;17(4):798-807. Epub 2007 Feb 16.

PMID:
17309668
17.
18.

Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study.

Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Denoux Y, Fiche M, Jacquemier J, Mathieu MC, Penault-Llorca F, Rigaud C, Roger P, Treilleux I, Vilain MO, Mathoulin-Pélissier S, Le Doussal V.

Histopathology. 2003 Apr;42(4):337-47.

PMID:
12653945
19.

Observer prediction of HER2 amplification in HercepTest 2+ breast cancers as a potential audit instrument.

Going JJ.

Histopathology. 2011 Aug;59(2):333-5. doi: 10.1111/j.1365-2559.2011.03879.x.

PMID:
21884213
20.

Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.

Dal Lago L, Durbecq V, Desmedt C, Salgado R, Verjat T, Lespagnard L, Ma Y, Veys I, Di Leo A, Sotiriou C, Piccart M, Larsimont D.

Mol Cancer Ther. 2006 Oct;5(10):2572-9.

Supplemental Content

Support Center